(Q52925310)

9 May 2018

title

Metformin and epithelial ovarian cancer therapeutics. (English)

1 reference

9 May 2018

1 reference

1 reference

Seema Patel

1

1 reference

9 May 2018

Lalit Kumar

series ordinal

2

1 reference

9 May 2018

Neeta Singh

series ordinal

3

1 reference

9 May 2018

publication date

13 August 2015

1 reference

9 May 2018

published in

Cellular Oncology

1 reference

9 May 2018

volume

38

1 reference

9 May 2018

issue

5

1 reference

9 May 2018

page(s)

365-375

1 reference

9 May 2018

Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits human ovarian cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Expression of H1.5 and PLZF in granulosa cell tumors and normal ovarian tissues: a short report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Apoptosis induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through intrinsic and extrinsic pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Primary culture and mRNA analysis of human ovarian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Drug repositioning summit: finding new routes to success.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Polymorphism in human organic cation transporters and metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Metformin induces apoptosis of pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13402-015-0235-7

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain

21 January 2018

1 reference

12 December 2020

Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells

1 reference

12 December 2020

The value of drug repositioning in the current pharmaceutical market

1 reference

12 December 2020

Apoptosis induction and anti-cancer activity of LeciPlex formulations

1 reference

12 December 2020

10.1007/S13402-015-0235-7

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018